![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, April 12, 2016 2:00:33 PM
I believe in 3 weeks we will be coming upon a portion of the last deal made to the existing investors.
Correct me if I'm wrong on this, but if I got it right, I am tossed between 2 scenarios:
- hoping the price goes above the $3.00 mark after the 60 day period (with no dilution)
- hoping for some news and having the price rise above $3.00 (with dilution)
That would mean 5,880,000 shares x $3.00 = $17,640,000
...at the current burn rate that would cover a quarter an a half.
I'm leaning toward waiting until May.
Would that not be better for us, unless the money was desperately needed?
http://www.nwbio.com/nw-bio-announces-registered-direct-offering-of-up-to-27-6-million-with-existing-institutional-investors/
FEB 2016
NW Bio Announces Registered Direct Offering Of Up To $27.6 Million With Existing Institutional Investor
BETHESDA, Md., February 29, 2016 – Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with current institutional investors for a registered direct offering with gross proceeds of up to approximately $27.6 million, assuming exercise in full of the overallotment option described below.
As part of the transaction, the Company will immediately sell approximately 5.88 million shares of common stock at a purchase price of $1.70 per share resulting in gross proceeds to the Company of $10 million. The investors will also receive warrants to purchase up to approximately 2.94 million shares of common stock with an exercise price of $2.25 per share. The warrants will have an exercise period of five years commencing on the 6-month anniversary of the warrant issuance.
In addition, Northwest granted to the investors a 60-day overallotment option to purchase up to an additional 5.88 million shares of common stock at a purchase price of $3.00 per share, for an aggregate purchase price of approximately $17.6 million. In connection with such purchase of shares pursuant to the overallotment option, the investors will receive warrants to purchase up to 2.94 million shares of the Company’s common stock with an exercise price of $4.00 per share and an exercise period of five years commencing on the 6-month anniversary of the warrant issuance.
The placement is expected to close on or about March 3, 2016, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction.
The securities described above are being offered pursuant to a shelf registration statement (File No. 333-207976), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on December 22, 2015. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC’s website at http://www.sec.gov or by request at H.C. Wainwright & Co., LLC, at placements@hcwco.com.
“You have not lived today until you have done something for someone who cannot pay you back!” - John Bunyon
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • Jul 18, 2024 9:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM